<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114516</url>
  </required_header>
  <id_info>
    <org_study_id>STU00019610</org_study_id>
    <nct_id>NCT01114516</nct_id>
  </id_info>
  <brief_title>Multifactorial Approach to Emergent Cerclage</brief_title>
  <acronym>RECIA</acronym>
  <official_title>Role in Emergent Cerclage of Indomethacin and Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Though cervical insufficiency is a common cause of second trimester pregnancy loss, the
      placement of an emergent cerclage in these patients is thought to improve perinatal outcomes.
      It is unknown whether the use of tocolytics and antibiotics prolongs pregnancies complicated
      by need for emergent cerclage.

      The objective is to determine whether administration of peri-operative antibiotics and
      indomethacin to patients receiving emergent cerclages for cervical insufficiency increases
      latency period to delivery compared with patients receiving emergent cerclage alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational Latency Achieved Between Cerclage Placement and Time of Delivery</measure>
    <time_frame>24 weeks</time_frame>
    <description>Median gestational latency achieved Between Cerclage Placement and Time of Delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational Latency of More Than 28 Days</measure>
    <time_frame>28 days postpartum</time_frame>
    <description>The frequency of achieving a gestational latency of more than 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>24 weeks</time_frame>
    <description>Median gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Morbidity and Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Days spent in the neonatal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Median birthweight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Cervical Insufficiency</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indomethacin and antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perioperative antibiotics and indomethacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin and antibiotics (cefazolin or clindamycin)</intervention_name>
    <description>q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
    <arm_group_label>indomethacin and antibiotics</arm_group_label>
    <other_name>indocin, cleocin, ancef</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GA 16+0 to 23+6 weeks

          -  Singleton gestation

          -  Presence of cervical dilation as diagnosed on digital examination

          -  Intact membranes

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Allergy to NSAIDs

          -  Renal disease

          -  Allergy to penicillins AND clindamycin

          -  Currently on antibiotics or indomethacin for any reason

          -  HIV positive

          -  Pregnancies complicated by fetal congenital anomalies

          -  Preterm premature rupture of membranes

          -  Fever of 100.4 degrees Fahrenheit or higher

          -  Any patient having received a therapeutic cerclage during the current pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Miller ES, Grobman WA, Fonseca L, Robinson BK. Indomethacin and antibiotics in examination-indicated cerclage: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1311-6. doi: 10.1097/AOG.0000000000000228.</citation>
    <PMID>24807330</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <results_first_submitted>September 8, 2014</results_first_submitted>
  <results_first_submitted_qc>October 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>William Grobman</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>cervical insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Incompetence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
        </group>
        <group group_id="P2">
          <title>Indomethacin and Antibiotics</title>
          <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
        </group>
        <group group_id="B2">
          <title>Indomethacin and Antibiotics</title>
          <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="4.9"/>
                    <measurement group_id="B2" value="31.9" spread="6.5"/>
                    <measurement group_id="B3" value="30.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gestational Latency Achieved Between Cerclage Placement and Time of Delivery</title>
        <description>Median gestational latency achieved Between Cerclage Placement and Time of Delivery</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin and Antibiotics</title>
            <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Latency Achieved Between Cerclage Placement and Time of Delivery</title>
          <description>Median gestational latency achieved Between Cerclage Placement and Time of Delivery</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="15" upper_limit="122"/>
                    <measurement group_id="O2" value="97" lower_limit="57" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan Meier survival analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Latency of More Than 28 Days</title>
        <description>The frequency of achieving a gestational latency of more than 28 days</description>
        <time_frame>28 days postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin and Antibiotics</title>
            <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Latency of More Than 28 Days</title>
          <description>The frequency of achieving a gestational latency of more than 28 days</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <description>Median gestational age at delivery</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin and Antibiotics</title>
            <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <description>Median gestational age at delivery</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="22.9" upper_limit="38.5"/>
                    <measurement group_id="O2" value="34.8" lower_limit="27.1" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.393</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Morbidity and Mortality</title>
        <description>Days spent in the neonatal intensive care unit</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin and Antibiotics</title>
            <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Morbidity and Mortality</title>
          <description>Days spent in the neonatal intensive care unit</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="11" upper_limit="112"/>
                    <measurement group_id="O2" value="43" lower_limit="19" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birthweight</title>
        <description>Median birthweight</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin and Antibiotics</title>
            <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Birthweight</title>
          <description>Median birthweight</description>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2488" lower_limit="955" upper_limit="3175"/>
                    <measurement group_id="O2" value="2850" lower_limit="1440" upper_limit="3380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>emergent cerclage with no peri-operative antibiotics or indomethacin</description>
        </group>
        <group group_id="E2">
          <title>Indomethacin and Antibiotics</title>
          <description>perioperative antibiotics and indomethacin
Indomethacin and antibiotics (cefazolin or clindamycin): q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because this study was not adequately powered to detect differences in perinatal outcomes, whether this adjunctive therapy affects these outcomes remains uncertain.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Emily Miller</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>3124724685</phone>
      <email>emily-miller-1@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

